A clinical study out of Italy on 94 children with autism showed that 83 of them made considerable progress while on GcMAF. The most common reported improvements involve:

• Cognitive abilities including attention and focus, learning and understanding, receptiveness and awareness of the environment and both receptive and expressive language gains.

• Social Skills including willingness to interact and communicate with peers.

• Behavior including less hyperactivity, less stereotypical behaviors and improved cooperation and compliance.

In another study of 1500 children with autism, 85% had high levels of viruses and a compromised immune system. All 1500 received weekly GcMAF injections and 70% of the children responded to the treatment with reduced symptoms and another 15% made full recoveries. The other 15% did not respond.

Gc-MAF hasn’t had the benefit of a single patent owner – as a natural molecule, it cannot be patented without being modified – with the will and resources to push it under the noses of the public and health authorities. Dr Yamamoto has run small human trials in breast, prostate and colorectal cancers, with promising results.

Bad law kills, and Britain has the worst medical laws in Europe. The 1939 Cancer Act makes it illegal to discuss the possibility cancer can be cured, which is partly why 160,000 people die unnecessarily of cancer in Britain every year. Science and treatments are decades ahead of where the medical industry is today. The MHRA’s job is to get life saving treatments like GcMAF out to people as quickly as possible. Instead they block them to protect billion dollar Big Pharma monopolies, who also fund the MHRA. Over a hundred thousand lives could be saved every year if the 1939 Cancer Act were repealed, and the MHRA were closed down.

Minutes after a receiving a dose, 10 of the body’s actions restart. In three weeks of two GcMAF 0.25ml doses a week, your immune system is rebuilt to above normal strength. You need two doses a week for typically 24 weeks for many diseases and early cancers, up to seven one ml doses a week and a year for stage 4 cancers. Your body then takes the disease down without side effects, and successfully in 80% of cases -depending upon how well you follow the protocol under “Treatment Protocol” on this website.

What is GcMAF?
It is a human protein. One week’s GcMAF looks like a small raindrop. If properly produced it is perfectly sterile, and a most ethical course for doctors.

GcMAF is therefore a replacement therapy for those who can’t make their own. Taking GcMAF replaces the missing part of the immune system, and also acts as the body’s own internal medicine.

GcMAF is extracted and isolated; its a 24 step process, and at the end it must have tests to prove its sterility and activity. (If it does not come with published tests, its probably not GcMAF.) One GcMAF has been tested in universities, laboratories and clinics, where, as a result of the testing, consistent activity and sterility have always been found, and been the subject of 40 scientific research papers.

What does GcMAF do?
The GcMAF Conference 2013 showed GcMAF is a far more powerful molecule than thought, both in terms of the science, and doctors’ results. In stage 4 cancer, some doctors who use the full protocol, listed on “Treatment Strategies,” are saving every patient (if they have not had chemotherapy.) Success can be achieved with all tumour cancers including breast, lung, prostate, pancreatic and melanoma.

GcMAF can eradicate chronic inflammation and viral infections. It is better than antibiotics in many areas, and 25% successful with Autism, 50% or more with Chronic Herpes, Chronic Acne, Chronic cirrhosis of the liver, Chronic kidney disease, Chronic depression, Colitis, Crohn’s, Fibromyalgia, Hepatitis, Herpes, LMBBS, ME/CFS, Osteoporosis, Periodontal disease, Psoriasis and various types of Immune dysfunction including allergies. Research shows GcMAF can halt deterioration in Parkinsons, multiple sclerosis (MS), dementia and ALS, and in its role of immune system regulator, can reverse diseases that attack the immune system like Lupus and Arthritis. And is effective with wound healing. Its successful with tumour cancers, and some others.

In addition to rebuilding a depressed immune system, GcMAF:
Inhibits angiogenesis – stops blood supply to tumours
Activates macrophages – phagocytosis and destruction of cancer cells
Apoptosis – suicide of cancer cells
Reverts the cancer cell phenotype to normal (Turns cancer cells into healthy cells)
Reduces the metastatic potential of human cancer cells in culture.
Increases energy production at the mitochondrial level – ME/CFS
Improves human neuronal metabolic activity through cAMP signaling – autism, ME/CFS, MS, ALS
Counters toxic effects including cadmium – ME/CFS

It abolishes neuropathic pain due to neuro-oxidative stress (stress due to the anti-cancer drug oxaliplatin) in the lab. (neurodegenerative diseases and autism that have oxidative stress as a pathogenetic mechanism)
It increases neuronal connectivity by promoting differentiation and the formation of dendrites and neuritis (autism and ME/CFS, where there is a lack of connectivity between neurons).

See the 31 research papers published, particularly Brescia, and the 60 published by others listed under “The science”.

80% of terminal stage four tumour cancers cases can be saved (40% if they’ve had chemo), but usually when they are closely monitored, which is why residential Treatment Centres are being run in Switzerland. If they have three months to live and have not had chemo, almost no one needs to be lost.

The 180 scientists who have published papers on trials of GcMAF selected those in the early stages of cancer and HIV, and reported nearly 100 percent success, with no recurrence after many years. They did not attempt trials on people with large tumours.

Our trials are quite different: many people are over 50, some over 80, with advanced or terminal cancers, with significant tumour mass. Most come to us when their doctors tell them they can do no more.

The life of GcMAF is only six days – you have to keep taking it until your disease has gone (ie your nagalase is under 0.65 nmol/min/mg) then a further 8 weeks, or the immune system gets shut down again.

How long should you take GcMAF for?
8 weeks for chronic herpes/acne, fibromyalgia, inflammation.
Allow 24 weeks plus of GcMAF for: Autism (85% improve, 25% eradication), CFS (70% eradication), HIV, Lyme (8% respond, most appear to have the VDR gene blocked and the viruses conceal themselves with biofilms) and stage 1 to 2 cancer, (80% respond).
Late stage cancer, if you follow “Treatment Protocol” again has 80% responders, but it takes a year to 18 months to become cancer free.
Cirrhosis of the liver: 16 months

Remember everyone responds differently. We can’t say how you will respond.

The more minor the disease, the easier it is for GcMAF to eradicate. GcMAF needs normal levels of vitamin D to function strongly (take 10,000iu a day). in low responders, larger doses are required.

We have probably proved GcMAF can work for people up to age 90, and can destroy large tumour mass. See “Participants experiences”.

If you have your blood taken for monocyte counts, relevant markers and vitamin D levels, and again for a nagalase test at the beginning, you should see on your next test after three weeks that your immune system is back to full strength, and after 8 weeks significantly falling nagalase will indicate the disease is losing its grip. Don’t stop the GcMAF until your nagalase gets below 0.65 nmol/min/mg, when it loses the ability to prevent your body producing your own GcMAF, and then you no longer need ours. Even better, get scans.

Autism children can improve at five weeks with substantial improvements at 8 weeks. See “Participants experiences.” But everyone is different.

The beauty of using your own immune system to attack disease or cancer is that it remembers how to defeat it for the rest of your life: it doesn’t come back. And unlike chemotherapy, the side effects are trivial.

The only way you can tell if GcMAF is genuine and active is to test with living cells in a laboratory. See “Quality and Tests of our GcMAF.” To recap:

We put live macrophages cells and MCF7 breast cancer cells together; nothing happens. Then we add GcMAF; in 72 hours the macrophages eat all the MCF7 cancer cells. We then put only GcMAF and MCF7 together, and the GcMAF turns the cancer cells back into healthy cells.

We have GcMAF available for preclinical trials. See “Buy GcMAF”.

Here are some points that I have learned thus far on GcMAF:

- GcMAF has reportedly been tested more for safety, purity, etc. than other human blood products.
- Macrophages are cultured, destroyed, and the GcMAF receptors are purified.
- Treatment is via injection 1x/week for 8-20 weeks. Dose is titrated initially to avoid exacerbation or Herx responses as much as possible.
- A commonly used dose is .25ml once weekly (a 2.2 ml vial should last 8 injections).
- The primary test used in looking at whether or not GcMAF may be a reasonable intervention is nagalase.
- Nagalase inactivates macrophages.
- I personally would NEVER consider this option without having a baseline nagalase test. Normal is
The practitioner I worked with suggested that 2.9 was in the range of someone with HIV or cancer in terms of the impact on the immune system. I’d like to hear from others in the Lyme community as you get test results as well to see if there is a pattern of elevated nagalase in those with Lyme disease. Whether or not Lyme itself has anything to do with nagalase elevation is something I have not been able to find anything on. We certainly all have underlying viral co-factors that are likely in play as well, but I suspect that Borrelia may also play a role in nagalase elevation.

- In healthy college students, a nagalase 0.4 is not uncommon (the lower the better).

- At 2.9, my practitioner was surprised that I did not have more cognitive deficits such as memory loss and other cognitive issues.

- It has been suggested that ongoing antimicrobial therapy without a working immune system is like leaving the house with the door wide open inviting burglars in. By using GcMAF to activate macrophages, nagalase drops, and one may regain a functional immune system. The door is then closed to further invaders and we may no longer serve as a microbe hotel.

- Maintenance therapy should not be needed once the immune system is once again properly functioning.

- Activated macrophages only remain active for 7 days so any negative responses are generally short-lived. That said, some people do have strong inflammatory responses that are not believed to be typical die-off reactions.

- It has been indicated that in some cases, other medications may be needed in order to manage the inflammatory response. This is another reason that one needs to be working closely with a knowledgeable practitioner before considering GcMAF in my opinion. In the CFS and GcMAF world, this more severe form of a die-off reaction is called IRIS.

- VDR genetics do not seem to play a role in predicting response as earlier thought according to one practitioner that I have spoken with. That said, Vitamin D levels do correlate with the positive response rate of GcMAF. Thus, Vitamin D supplementation may be required in order to optimize outcome.

- Other than die-off reactions or activation of symptoms (inflammation), no other side effects are generally expected.

- Nagalase should be monitored every 1-2 months while on treatment to determine the required duration of the therapy. Target nagalase after treatment would be 0.4 to 0.6.

- Elevated nagalase has a profound detrimental effect on the immune system. Elevated nagalase is often presumed to be related to microbes of viral origin or cancer. Viruses that are nagalase producers open the door to chronic infections.

- Hemagglutinin contains nagalase and is also found in flagella of some bacteria so it could also be the case that some bacteria may produce nagalase.

- Parents with ASD children also often have elevated nagalase.

- A practitioner I spoke with likened Lyme disease to a “peat moss fire” burning below the surface. Activating macrophages should help to deal with the fire.

- GcMAF should be helpful in dealing with other infections that are not of viral origin; for example, Borrelia, Bartonella, and other infections commonly associated with Tick-Borne Infections (TBIs). GcMAF is active against many cancers and many different kinds of microbes.

- Neopterin is another test that is sometimes used as an indicator of immune suppression. As macrophages become activated, neopterin may rise and later fall. If one is in the normal range for neopterin and has an immune-related illness, this could be an indication that the immune system is suppressed and not responding appropriately.

- People with autoimmune conditions can generally use GcMAF. However, GcMAF may be contraindicated in people with Multiple Sclerosis.

- Reduction in nagalase is generally seen early in the course of treatment; within the first 3-6 weeks. In some studies, nagalase dropped by over 50% in less than six weeks.

- Cancer patients may initially feel as bad on GcMAF as they do on chemotherapy, but often feel much better after the first month.

- Anti-inflammatories may limited the effect of GcMAF.

- Enzymes and biofilm-reducing supplements may have a negative impact on GcMAF therapy and may be best avoided. It is still too early to know what the impact may be, but one practitioner I spoke with feels that it is best to avoid these.

- One should not be on any immune-suppressing agents while on GcMAF as the immune system must be partially functional in order to respond appropriately to the treatment.